Clinical trial
A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
NCT00390676 · Adherex Technologies, Inc., Industry · Completed
Key facts
| NCT number | NCT00390676 |
|---|---|
| Title | A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine |
| Official title | A Phase 1, Multicenter, Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in Subjects With N-Cadherin Positive, Advanced Solid Tumors (Adherex Protocol Number AHX-01-006) |
| Lead sponsor | Adherex Technologies, Inc., Industry |
| Collaborators | US Oncology Research Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | ADH -1 and carboplatin, ADH -1 and docetaxel, ADH -1 and capecitabine |
| Start date | Nov 1, 2006 |
| Completion | Nov 1, 2009 |
| First posted | Oct 20, 2006 |
| Last update posted | Dec 28, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: